Search

Displaying results 3341 - 3350 of 7607 in total
  1. Drug

    Furaprevir

    go.drugbank.com/drugs/DB12785
    Investigational

    Furaprevir is under investigation in clinical trial NCT01523990 (A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients).

  2. Drug

    Tipranavir

    go.drugbank.com/drugs/DB00932
    ApprovedInvestigational

    Tipranavir and ritonavir are coadministered to treat HIV.

  3. Drug

    Serotonin

    go.drugbank.com/drugs/DB08839
    InvestigationalNutraceutical

    Not evaluated by the FDA, homeopathic product.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Talopram

    go.drugbank.com/drugs/DB09190
    Experimental

    Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.

  5. Drug

    Demegestone

    go.drugbank.com/drugs/DB13857
    Experimental

    Demegestone is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was previously marketed in France as Lutionex, but has since been discontinued.

  6. Drug

    Azimilide

    go.drugbank.com/drugs/DB04957
    Investigational

    It is not approved for use in any country, but is currently in clinical trials in the United States.

  7. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4. … Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections.

  8. Drug

    Piretanide

    go.drugbank.com/drugs/DB02925
    Approved

    Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in

  9. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer … Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.

  10. Drug

    BMS-791826

    go.drugbank.com/drugs/DB15023
    Investigational

    BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).